loading

Xortx Therapeutics Inc (XRTX) 最新ニュース

pulisher
May 01, 2025

XORTX Therapeutics Delays Yearly Report Filing - TipRanks

May 01, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Higher in U.S. Pre-market Trading, Says FDA Type B Meeting Positive - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Provides Update On FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Brief: Providing Update on FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Provides Update on FDA Type B Meeting Request - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Inc. Provides Update on FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025
pulisher
Apr 28, 2025

XORTX Therapeutics Inc. Announces Grant of European Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

XORTX Secures European Patent for Gout and Kidney Disease Therapies - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

XORTX Announces Grant of European Patent - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

XORTX Secures Game-Changing European Patent for Gout and Kidney Disease Treatments - Stock Titan

Apr 28, 2025
pulisher
Apr 18, 2025

XORTX Therapeutics receives Nasdaq notice for non-compliance - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge - GuruFocus

Apr 18, 2025
pulisher
Apr 18, 2025

XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency - MSN

Apr 18, 2025
pulisher
Apr 17, 2025

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

XORTX Faces Nasdaq Price Compliance Challenge: 180 Days to Avoid Delisting Risk - Stock Titan

Apr 17, 2025
pulisher
Apr 11, 2025

XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX) - The Globe and Mail

Apr 11, 2025
pulisher
Apr 09, 2025

1 Defense Stock to Buy for Protection During These Uncertain Times - The Globe and Mail

Apr 09, 2025
pulisher
Apr 01, 2025

XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks

Apr 01, 2025
pulisher
Mar 26, 2025

XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks

Mar 26, 2025
pulisher
Mar 19, 2025

XORTX Announces Update for Discussion with the FDA - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan

Mar 19, 2025
pulisher
Feb 24, 2025

Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan

Feb 24, 2025
pulisher
Feb 15, 2025

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com

Feb 15, 2025
pulisher
Jan 29, 2025

XORTX to Present at Microcap Conference - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks

Jan 29, 2025
pulisher
Jan 29, 2025

Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

XRTXXortx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Jan 29, 2025
pulisher
Jan 24, 2025

XORTX Therapeutics Announces Auditor Transition - MSN

Jan 24, 2025
pulisher
Jan 22, 2025

XORTX Announces Change of Auditor - TipRanks

Jan 22, 2025
pulisher
Jan 21, 2025

XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

XORTX Therapeutics Announces Auditor Change to Davidson & Company LLP - StockTitan

Jan 17, 2025
pulisher
Jan 16, 2025

XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel

Jan 16, 2025
pulisher
Jan 15, 2025

Now Is The Time To Build A Position In XORTX Therapeutics Inc (NASDAQ:XRTX) - Marketing Sentinel

Jan 15, 2025
pulisher
Jan 06, 2025

XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

XORTX Adds Late Stage Gout Program to Pipeline - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

XORTX Launches XRx-026 Program for Allopurinol-Intolerant Gout Patients, Targets FDA Approval - StockTitan

Jan 06, 2025
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
大文字化:     |  ボリューム (24 時間):